Outstanding Companies, Individuals, and Scientific Achievements are
at the 20th Biotech Meeting, Laguna Niguel
LAGUNA NIGUEL, Calif., Oct. 8 /CNW/ -- At the 20th Annual Biotech Meeting
at Laguna Niguel, a biotech CEO-only conference hosted by Burrill & Company
and Kleiner Perkins Caufield & Byers, inductees into the Biotech Hall of Fame
were announced at an Awards Dinner held here Sunday evening.
For twenty years, the CEOs of the biotech industry have recognized the
outstanding achievements of the past year, heralding colleagues, companies
behind the scientific breakthroughs and business success. To commemorate the
20th year of the Biotech meeting CEO's voted on a slate of nominees for three
categories: Leading Company, Special Recognition for an Individual, and
Scientific Achievement. The nominees were selected by G. Steven Burrill, CEO,
Burrill & Company, Brook Byers, Senior Partner at Kleiner, Perkins, Caufield &
Byers and a special advisory committee. Unlike the previous award processes,
the nominations were not made on the basis of the past year's performance but
their total contribution to the biotechnology industry. The inductees are:
Lead products include THALOMID for the treatment and suppression of
cutaneous manifestations of erythema nodosum leprosum, an inflammatory
complication of leprosy. The company's products also include REVLIMID
for the treatment of patients with transfusion-dependent anemia.
Current market cap is $28 billion.
A leader in innovative products and services for a variety of
veterinary, food and water applications. Their companion animal and
equine businesses combine biotechnology with medical devices and
information technology to support veterinarians.
Developer, manufacturer and marketer of next-generation life-science
tools and integrated systems for the large-scale analysis of genetic
variation and biological function.
Developer of innovative small molecule cancer treatments based on a
molecular understanding of cancer. Onyx's lead product is Nexavar(R)
(sorafenib) tablets, an oral multiple kinase inhibitor that targets
proteins involved in both tumor cell proliferation and angiogenesis
(the formation of new blood vessels to support cancer cell growth).
The Company is leading the development of the HCV protease inhibitor,
telaprevir (VX-950), and in 2007 is conducting a broad Phase 2
clinical program of this drug candidate. Vertex is also focused on the
development of VX-702, a p38 MAP kinase inhibitor for the treatment of
rheumatoid arthritis, and VX-770, an investigational drug candidate
for cystic fibrosis.
Special Recognition for an Individual
Jim Greenwood, President and CEO, Biotechnology Industry Organization
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations in
all 50 U.S. states and 31 other nations.
Susan D. Desmond-Hellmann, President, Product Development, Genentech
Genentech is one of the biotech industry's leading companies and Dr.
Desmond-Hellmann has overseen the development of several promising
cancer drugs and the final testing phase of others.
John C. Martin, President and CEO, Gilead Sciences Inc.
Dr. Martin joined Gilead Sciences in 1990 and has served as President
and Chief Executive Officer since 1996. The company has expanded
rapidly over the past two decades, with annual revenues now exceeding
Ed Penhoet, Co-Founder of Chiron Corp.
He was president and CEO of the prominent biotechnology company until
May 1998. He has held leadership positions in the biotechnology
industry and in academia, and is currently vice chair of the
state-appointed board overseeing California's $3 billion stem cell
Hollings C. Renton, Chairman, President and CEO, Onyx Pharmaceuticals
He has served as President, Chief Executive Officer and Director of
the company since 1993. Prior to joining Onyx, Mr. Renton was the
President and Chief Operating Officer of Chiron Corporation.
Harold E. Varmus and J. Michael Bishop
Co-recipients of the 1989 Nobel Prize in Physiology or Medicine for
their discovery of the cellular origins of retroviral oncogenes. They
directed the research that led to the discovery of proto-oncogenes --
normal genes that can be converted to cancer genes by genetic damage.
This work eventually led to the recognition that all cancer probably
arises from damage to normal genes, and provided new strategies for
the detection and treatment of cancer.
Director of the National Human Genome Research Institute (NHGRI) at
the National Institutes of Health (NIH). He led the successful effort
to complete Human Genome Project (HGP), a complex multidisciplinary
scientific enterprise directed at mapping and sequencing all the human
DNA, and determining aspects of its function.
Dr. Ferrara and his team of scientists at Genentech Inc. made a
groundbreaking discovery that added greatly to our understanding and
treatment of cancer. It was the identification and cloning of a gene
termed vascular endothelial growth factor, or VEGF, which produces a
protein that plays a critical role in angiogenesis.
Andrew Z. Fire and Craig C. Mello
Co-recipients of the 2006 Nobel Prize in Physiology or Medicine for
their discovery of RNA interference -- gene silencing by
double-stranded RNA. RNA interference occurs in plants, animals, and
humans. It is of great importance for the regulation of gene
expression, participates in defense against viral infections, and
keeps jumping genes under control. RNA interference is widely used in
basic science as a method to study the function of genes and it may
lead to novel therapies.
In 1999 Forbes magazine named Prof. Langer, Department of Chemical
Engineering, Massachusetts Institute of Technology, as one of the 25
most important individuals in biotechnology in the world. His work is
at the interface of biotechnology and materials science. A major focus
is the study and development of polymers to deliver drugs,
particularly genetically engineered proteins, DNA and RNAi,
continuously at controlled rates for prolonged periods of time.
"There is no greater recognition than that of one's peers," commented G.
Steven Burrill, CEO of Burrill & Company, "and we are delighted to recognize
these outstanding inductees to the Biotech Hall of Fame."
The Biotech Meeting at Laguna Niguel is the premier industry conference
exclusively for CEOs of biotechnology companies. The Biotech Meeting (now in
its 20th year) is held annually at The Ritz-Carlton Hotel in Laguna Niguel
(Southern California). It is running October 8-9, 2007 and over 250 leading
biotech CEOs have gathered to share management ideas, set an agenda for the
industry and network with each other.
About Kleiner Perkins Caufield & Byers
Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed
entrepreneurs in 475 ventures, including AOL, Align, Amazon.com, Citrix,
Compaq Computer, Electronic Arts, Genentech, Genomic Health, Google, IDEC
Pharmaceuticals, Intuit, Juniper Networks, Netscape, Lotus, LSI Logic, Sun
Microsystems, Symantec, Verisign, and Xilinx. More than 150 of the firm's
portfolio companies have gone public. Many other ventures have achieved
success through mergers and acquisitions. KPCB has broadly invested in both
life sciences and information technology since inception in 1972. In the last
seven years, KPCB has expanded its focus to include Greentech and pandemic
preparedness. http://www.kpcb.com/greentech . KPCB has committed more than
$200 million to 25 Greentech ventures over the past seven years, including
Altra Biofuels, Amyris Biotechnologies, Ausra, Bloom Energy, Great Point
Energy, Mascoma, Miasole, and Verdiem.
About Burrill & Company
Burrill & Company is a San Francisco-based global leader in life sciences
with principal activities in Venture Capital, Merchant Banking and Media. The
company's over 50-person scientific and business team, supported by its
Advisory Boards, the strategic and financial network of its limited partners,
and the close relationships developed with numerous life science companies and
managements, provide Burrill with unparalleled access and insight. The Burrill
Life Sciences Media Group, a joint venture of Burrill & Company and Nielsen
Business Media, produces worldwide life sciences conferences, and leading
publications including an annual book on the "State of the Industry, the 21st
Edition is Biotech 2007: Life Sciences-A Global Transformation; a series of
bio-intelligence reports, The Journal of Life Sciences, in association with
the California Healthcare Institute, and the Burrill Biotechnology
Intelligence Report, which tracks the progress of the industry through its
Burrill Biotech Indices and monthly financial analysis of the deals,
partnerships and M&As.
For further information:
For further information: Peter Winter, Editorial Director of Burrill
Life Science Media Group, +1-415-591-5474, Cell, +1-415-200-8163,
firstname.lastname@example.org Web Site: http://www.burrillandco.com